Introduction
============

Peripheral arterial disease (PAD) is an atherosclerotic disease that affects lower extremities. The risk factors for PAD are the same as those for atherosclerosis in general and include male sex, advanced age, cigarette smoking, hypertension, diabetes, and hyperlipidaemia ([@b11]).

PAD is a marker of advanced atherosclerosis with an elevated risk of cardiovascular mortality and morbidity. Patients with PAD have a 4 fold increased risk of myocardial infarction ([@b9]) and a 2--3-fold increased risk of stroke ([@b24]) compared to persons without PAD. Furthermore, the risk of cardiovascular mortality and morbidity in patients with PAD is comparable to that in patients with coronary artery disease (CAD) ([@b5]).

Reducing the adverse cardiovascular outcomes of atherosclerosis through risk factor identification and modification has been an active area of research over the past few decades. Since PAD is a marker of advanced atherosclerosis with an elevated risk of cardiovascular mortality and morbidity, intensive risk reduction therapy is critical in these patients. Risk reduction therapy such as smoking cessation, blood sugar control, blood pressure control, antiplatelets, statin, and angiotensin converting enzyme (ACE) inhibitors are proven therapy in reducing the risk of cardiovascular mortality and morbidity in PAD patients ([@b21]; [@b25]; [@b4]; [@b12]; [@b16]; [@b23]). These results have led several expert committees in recommending their use patients with PAD ([@b1]; [@b15]; [@b19]).

Although the adverse outcomes in patients with PAD are well documented, the awareness of this information among all physicians is felt to be low ([@b14]). The knowledge and implementation of atherosclerotic risk factors reduction in PAD patients have been shown to be suboptimal among general practitioners, internal medicine specialists, cardiologists, and vascular surgeons in the United States, Canada and the United Kingdom ([@b13]; [@b17]; [@b6]; [@b7]; [@b2]).

The knowledge and implementation of risk factors reduction in patients with PAD among physicians in Saudi Arabia are not known and given the central role of physicians practicing in academic institutes in disseminating the standard of care in treating various diseases, this study was performed to assess the knowledge of the recommended target levels for blood pressure, blood glucose and LDL-cholesterol and knowledge and attitude towards risk reduction therapy in patients with PAD among physicians practicing in a major teaching hospital in Saudi Arabia.

Methods
=======

A self-administered questionnaire was mailed to all family physicians, general internists, cardiologists and vascular surgeons working at King Khalid University Hospital (KKUH) in Riyadh, Saudi Arabia in March 2006. KKUH is the major teaching hospital for the college of medicine, King Saud University; which is the oldest and largest medical school in Saudi Arabia. The questionnaire was based on a previously published questionnaire with some modifications ([@b2]). The questionnaire was anonymous and physicians were consented before participation. This study was approved by KKUH Ethics Review Board.

The survey contained multiple-choice questions (Appendix). The questions requested information from participants regarding their demographics (age, gender, specialty, board certification status, years of experience), their knowledge about target levels of blood pressure, LDL-cholesterol, and blood glucose in patients with PAD, in addition to their attitudes toward patient counseling about cardiovascular risk reduction; comfort with recommending and instituting risk reduction therapy (smoking cessation, antiplatelets; statin; ACE inhibitors; and antihypertensive medications), factors that influence adequate risk reduction therapy delivery in PAD patients, proportion of patients with PAD who have their vascular risk factors evaluated systematically by the participants, and their self-assessment of PAD risk reduction knowledge.

All survey results are expressed as percentages. The number of respondents who completed each question provided the denominator for proportions of responses. The prespecified subgroups for analysis were specialty type (family physicians versus general internists versus cardiologists versus vascular surgeons). Chi-square tests were used to compare proportions between different subgroups. All p-values reported were two tailed, and were considered significant at the 0.05 level.

Results
=======

Fifty one of the 84 surveyed physicians at KKUH completed the survey, representing a response rate of 60.7%. Family physicians, general internists, cardiologists and vascular surgeons represent 39%, 33%, 16%, and 12% of the surveyed physicians, respectively. The results are depicted in [Tables 1](#tbl1){ref-type="table"}-[4](#tbl4){ref-type="table"}.

Physicians' characteristics
---------------------------

Two third of participated physicians are board certified in their specialties. Almost half of the respondents were practicing for more than 10 years ([Table 1](#tbl1){ref-type="table"}).

###### 

Characteristics of physicians who completed the survey by specialty (N = 51)

  -------------------------------------------------------------------------------------------------------------------
                        Family physicians\   General internists\   Cardiologists\   Vascular surgeons\   All\
                        (N = 20)             (N = 17)              (N = 8)          (N = 6)              (N = 51)
  --------------------- -------------------- --------------------- ---------------- -------------------- ------------
  Response rate,%       66.7                 53.1                  53.3             85.0                 60.7

  Mean age, y, +/− SD   43.2 +/− 5.2         39.7 +/− 7.2          38.8+/− 6.5      39.5+/--4.2          40.8+/−5.3

  Male gender,%         55.0                 64.7                  100              100                  70.6

  Board-certified,%     60.0                 58.8                  87.5             50.0                 66.7

  Years in Practice                                                                                      

   \<5 years,%          10.0                 29.4                  62.5             66.8                 31.4

   5--10 years,%        25.0                 29.4                  12.5             16.6                 23.5

   \>10 years,%         65.0                 41.2                  25.0             16.6                 45.0
  -------------------------------------------------------------------------------------------------------------------

Physicians' knowledge and attitude
----------------------------------

The knowledge of the surveyed participants for the recommended targets of LDL-cholesterol and blood pressure was low, on the other hand their knowledge for the recommended target level of blood glucose was high ([Table 2](#tbl2){ref-type="table"}). Only 21.6% knew that ACE inhibitor can be initiated in PAD patients irrespective of the blood pressure status, as an anti-atherosclerotic therapy ([Table 2](#tbl2){ref-type="table"}). Eighty five percent of the surveyed physicians indicated that their self assessment of risk reduction in PAD was average to below average.

###### 

Knowledge of physicians participated in the survey of risk reduction in patients with peripheral arterial disease expressed in percentage

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                     Family physicians\   General internists\   Cardiologists\   Vascular surgeons\   All\
                                                                                     (N = 20)             (N = 17)              (N = 8)          (N = 6)              (N = 51)
  ---------------------------------------------------------------------------------- -------------------- --------------------- ---------------- -------------------- ----------
  *Perception for the main cause of morbidity and mortality in patients with PAD:*                                                                                    

   Limb loss                                                                         30.0                 11.8                  37.5             0                    21.6

   Perioperative complications                                                       10.0                 0                     0                0                    3.9

   Cardiovascular events                                                             60.0                 88.2                  62.5             100                  74.5

  *Knowledge of the current recommended target of:*                                                                                                                   

   LDL-Cholesterol (\<2.5 mmol/l)                                                    35.0                 35.3                  62.5             16.7                 37.3

   Blood Pressure (\<130/80 mmHg)                                                    30.0                 35.3                  75.0             0                    35.3

   Blood Glucose (Hb1Ac \< 7%)                                                       100                  100                   100              66.7                 94.1

  *Knowledge of the relationship between BP and ACE inhibitors in PAD patients:*                                                                                      

   Not indicated in normal BP                                                        15.0                 17.6                  0                0                    11.7

   Initiate irrespective to BP status                                                20.0                 11.8                  50.0             16.7                 21.6

   Unclear about recommendations                                                     65.0                 70.6                  50.0             83.3                 66.7

  *Self-assessment of PAD risk reduction knowledge:*                                                                                                                  

   Average                                                                           50.0                 35.3                  75.0             33.3                 47.0

   Above-average                                                                     30.0                 35.3                  25.0             66.7                 35.3

   Below-average                                                                     15.0                 29.4                  0                0                    15.6
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Attitude towards routine patients counseling with regard to the importance of risk factor control was suboptimal ([Table 3](#tbl3){ref-type="table"}). Apart from routine initiation of antiplatelets therapy (86.3%), the attitude towards routine initiation and/or modification of other risk reduction therapy was very poor especially for initiating ACE inhibitors (17.7%). The highest threshold for initiating different risk reduction therapies was observed among general internist compared to other specialists, however, it was only statistically significant for initiating statin therapy (p = 0.025). On the other hand, cardiologists appeared to have the lowest threshold in initiating these therapies; however, it was not statistically significant for any therapy ([Table 3](#tbl3){ref-type="table"}). Two third of participants evaluate less than half of their PAD patients for vascular risk factors ([Table 3](#tbl3){ref-type="table"}).

###### 

Attitude of physicians participated in the survey towards risk reduction in patients with peripheral arterial disease expressed in percentage

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                       Family physicians\   General internists\   Cardiologists\   Vascular surgeons\   All\
                                                                                       (N = 20)             (N = 17)              (N = 8)          (N = 6)              (N = 51)
  ------------------------------------------------------------------------------------ -------------------- --------------------- ---------------- -------------------- ----------
  *Proportion of patients with PAD assessed for risk factors by the participant:*                                                                                       

   None                                                                                10.0                 11.8                  0                0                    7.8

   \<50%                                                                               60.0                 47.0                  37.5             16.7                 47.1

   \>50%                                                                               25.0                 41.2                  62.5             83.3                 43.1

  *Attitude towards routine evaluation of risk factors:*                                                                                                                

   Lipid profile measurement                                                           95.0                 88.2                  100              83.3                 92.1

   Blood pressure measurement                                                          100                  100                   100              83.3                 98.0

   Blood glucose measurement                                                           95.0                 100                   87.5             66.7                 92.1

   Asking about smoking                                                                85.0                 100                   87.5             100                  92.1

  *Attitude towards routine patients counselling with regards to the importance of:*                                                                                    

   LDL-cholesterol reduction                                                           90.0                 70.6                  75.0             83.3                 80.4

   Blood pressure control                                                              100                  94.1                  87.5             83.3                 94.1

   Blood glucose control                                                               95.0                 100                   87.5             83.3                 92.1

   Smoking cessation (advise to stop)                                                  85.0                 100                   87.5             100                  92.1

  *Attitude towards routine initiating/modifying risk reduction pharmacotherapy:*                                                                                       

   Statin                                                                              65.0                 41.1                  87.5             83.3                 62.7

   ACE inhibitor                                                                       25.0                 5.88                  37.5             0                    17.7

   Anti-hypertensive                                                                   75.0                 58.8                  87.5             33.3                 66.7

   Anti-platelets                                                                      85.0                 76.4                  100              100                  86.3

   Nicotine replacement therapy                                                        20.0                 17.6                  50.0             33.3                 25.5

   Referral to smoking cessation program                                               10.0                 29.4                  12.5             0                    15.6
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Barriers for delivering risk reduction therapy
----------------------------------------------

The barriers for not receiving adequate risk reduction therapy with the participants' responses are shown in [Table 4](#tbl4){ref-type="table"}.

###### 

Barriers for delivering risk reduction therapy in patients with peripheral arterial disease as viewed by physicians participated in the survey expressed in percentage

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Barriers                                                               Family physicians\   General internists\   Cardiologists\   Vascular surgeons\   All\
                                                                         (N = 20)             (N = 17)              (N = 8)          (N = 6)              (N = 51)
  ---------------------------------------------------------------------- -------------------- --------------------- ---------------- -------------------- ----------
  Lack of knowledge of treating physicians about PAD                     10.0                 5.9                   12.5             0                    7.8

  Lack of PAD management guidelines                                      35.0                 29.4                  0                16.7                 25.5

  Absence of continuing education about risk reduction therapy for PAD   10.0                 23.5                  25.0             16.7                 17.6

  Absence of vascular medicine specialist                                5.0                  0                     0                0                    2.0

  Combination of all above factors                                       40.0                 41.2                  62.5             66.6                 47.1
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

Patients with PAD generally have widespread arterial disease and therefore are at a significantly increased risk of stroke, myocardial infarction, and cardiovascular death ([@b22]). Coronary artery disease (CAD) is the most common cause of death in patients with PAD and accounts for 40%--60% of deaths. Stroke accounts for 10%--20% of deaths. Only 20% to 30% of patients with PAD die of non-cardiovascular causes ([@b22]). Patients with PAD have a 6 fold increased risk of cardiovascular disease mortality compared to patients without PAD ([@b9]). Therefore, intensive risk reduction therapy is critical in these patients to reduce the adverse cardiovascular outcomes. Risk reduction pharmacotherapy (antiplatelets, statins, and ACE inhibitors) are proven therapy in reducing the risk of cardiovascular mortality and morbidity in PAD patients in large scale randomized clinical trials ([@b25]; [@b4]; [@b12]). On the other hand, although there are no randomized clinical trials to prove the role of smoking cessation and blood sugar control in reducing the adverse cardiovascular outcomes in patients with atherosclerosis; large observational studies showed their effect to do so ([@b16]; Stratton et al 2004).

The compelling evidence from the literature has led several expert panels to recommend atherosclerotic risk reduction therapy use in all patients with PAD ([@b10]; [@b20], [@b19]; [@b3]; [@b8]). Furthermore, with the increasing recognition of the disease burden in patients with PAD, separate guidelines have been published to encourage the use of risk reduction therapies ([@b1]; [@b15]).

Although there is strong evidence supporting the importance of using risk reduction therapy in patients with PAD, in this study we have shown that despite the majority of surveyed physicians evaluate and counsel patients with PAD for their risk factors, knowledge and action remain suboptimal, and clear gaps have been identified. Majority of surveyed physicians rated their knowledge about risk reduction as average or above average; however, there is deficiency in the knowledge of the recommended target levels of blood pressure and LDL-cholesterol levels. In addition, minority of the participants knew that ACE inhibitor can be used in PAD patients irrespective to the blood pressure status for reducing atherosclerotic complications and cardiovascular death. Furthermore, there was also deficiency in initiating risk reduction therapy especially for ACE inhibitors and anti-smoking therapies. The action gap was most prominent among general internists compared to other specialties.

Our findings could be explained by the absence of national or locally adapted guidelines in managing patients with PAD and the reluctance of physicians to apply CAD guidelines to the PAD patient population even though the risks are similar, if not higher ([@b9]). Furthermore, the suboptimal use of ACE inhibitors could be explained by the fact that the evidence supporting the use of ACE inhibitors in patients with PAD to reduce the risk of adverse cardiovascular events is not a level A evidence and also dependent on the presence of symptoms (class IIa recommendation for symptomatic patients with PAD and Class IIb recommendation for asymptomatic patients) ([@b15]).

Knowledge and action gaps in managing risk factors in patients with PAD also have been shown among physicians in the United Kingdom, the United States and Canada ([@b17]; [@b18]; [@b7]; [@b2]). [@b7] showed that over a quarter of the UK vascular surgeons would not screen for diabetes or measure blood pressure in patients with PAD and only 34% of them would treat claudicants if the cholesterol was greater than 5.5 mmol/l. McDeermott et al (2002) showed that only 45.5% of the internal medicine physicians (IMP) prescribe antiplatelets to patients with PAD compared to 52.5% of the vascular surgeons, and only 16.8% of the vascular surgeons knew the large effect of cholesterol lowering on the risk of future cardiovascular events in patients with PAD compared to 43.6% of the IMP. Furthermore, even in cardiologists who were surveyed there was knowledge and action gaps in dealing with atherosclerotic risk. [@b2] showed that the utilization of risk reduction pharmacotherapy and the knowledge of the recommended target levels of blood glucose, blood pressure and LDL-cholesterol levels in patients with PAD among Canadian vascular surgeons were suboptimal. Furthermore, Mukherjee et al showed a suboptimal use of lifestyle modifications such as smoking cessation, exercise, weight reduction and diet for lipid control, and the use of evidence-based therapy such as antiplatelets therapy, ACE-inhibitors, beta-blockers, and statins in patients undergoing peripheral vascular interventions for PAD at hospital discharge and at 6 months follow-up ([@b18]).

The knowledge and action gaps in managing risk factors in patients with PAD from the previously published studies ([@b17]; [@b7]; [@b2]) along with our data add support to the available literature documenting inequities in use of risk reduction therapies for patients with PAD in comparison to patients with CAD ([@b14]). Furthermore, this data can be useful in supporting a call to action for PAD management and public awareness ([@b14]).

In the evaluation of these results, certain limitations merit emphasis. The small number of the participants included in this survey. It is also important to stress that this survey reflects the practice of physicians in a single teaching institute, and may not be generalizable to other hospitals. Also, since the data represent self-reported perceptions of knowledge they may underestimate the true gap. In addition, the survey form did not differentiate between symptomatic and asymptomatic PAD with regard to the use of ACE inhibitors as a risk reduction therapy.

In conclusion, the perceptions towards risk reduction in PAD identify glaring knowledge and action gaps, despite a considerable effort to evaluate and counsel patients for their risk factors. Given the heightened risk of cardiovascular adverse outcomes in patients with PAD, these data have important and immediate implications. If the current practice continues, the observed knowledge and action gaps are expected to persist. These findings may be useful for guiding targeted interventions such as locally adapted clinical practice guidelines in managing patients with PAD, self audit of practice, focused continuing medical education programs, the inclusion of risk reduction pharmacotherapy as a plenary topic at scientific meetings, and other educational outreach programs that aim to bring physicians' practice into agreement with current guidelines for cardiovascular risk reduction.

Note
====

Presented in part at the 7^th^ International Congress of the Asian Society for Vascular Surgery, Kuala Lumpur, Malaysia, August 2006.

**The survey questionnaire**

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------- ------------------
  Please encircle the chosen answer                                                                                                                                                                                                                                
  What is your age?                                                                                                                                                       \-\-\-\-\-\-- years                                                                      
  What is your gender ?                                                                                                                                                   Male                                                                      Female         
  What's your speciality? General practitioner                                                                                                                            Internist                                                                 Cardiologist   Vascular surgeon
  Are you board certified?                                                                                                                                                Yes                                                                       No             
  Hospital name and city?                                                                                                                                                 .................../...................                                                  
  Nationality?                                                                                                                                                            ....................................\...                                                 
  How many are you in practice in your speciality?                                                                                                                        \<5 years                                                                 5--10 years    \>10 years
  What do you perceive as being the main cause of morbidity and mortality in patients with PAD?                                                                           a\) Limb loss                                                                            
  b\) Perioperative complications                                                                                                                                                                                                                                  
  c\) Cardiovascular events, including, MI,Stroke and Cardiovascular outcomes                                                                                                                                                                                      
  What proportion of your patients with PAD have their vascular risk factors evaluated systematically by your self?                                                       a\) None                                                                                 
  b\) \<50%                                                                                                                                                                                                                                                        
  c\) \>50%                                                                                                                                                                                                                                                        
  Please rate your knowledge of risk reduction therapies in PAD                                                                                                           a\) Average                                                                              
  b\) Below average                                                                                                                                                                                                                                                
  c\) Above average                                                                                                                                                                                                                                                
   *i) Diabetes mellitus*                                                                                                                                                                                                                                          
  If PAD patient is not diabetic, do you measure Random and/or fasting blood sugar as a screening tool?                                                                   Yes                                                                       No             
  What are the current recommendations with respect to glucose control in patients with diabetes?                                                                         a\) Unsure                                                                               
  b\) HbA1c \< 7% in all patients, with an effort to achieve HbA1c \< 6% ideally, if possible                                                                                                                                                                      
  c\) Fasting blood glucose of \< 10mmol/L                                                                                                                                                                                                                         
  Do you routinely counsel diabetic patients regarding the importance of diabetes control?                                                                                Yes                                                                       No             
   *ii) Cigarette smoking*                                                                                                                                                                                                                                         
  Do you routinely ask these patients about smoking history?                                                                                                              Yes                                                                       No             
  Do you routinely advise these patients to stop smoking?                                                                                                                 Yes                                                                       No             
  Do you routinely recommend nicotine replacement therapy and/or other proven cessation intervention in these patients?                                                   Yes                                                                       No             
  Do you refer these patients to smoking cessation program?                                                                                                               Yes                                                                       No             
   *iii) Lipid control*                                                                                                                                                                                                                                            
  Do you routinely measure lipid values?                                                                                                                                  Yes                                                                       No             
  What are the current LDL-cholesterol target level in patients with PAD?                                                                                                 a\) Unsure                                                                               
  b\) less than 3.5 mmol/L                                                                                                                                                                                                                                         
  c\) less than 4.5 mmol/L                                                                                                                                                                                                                                         
  d\) less than 2.5 mmol/L                                                                                                                                                                                                                                         
  e\) less than 1.7 mmol/L                                                                                                                                                                                                                                         
  Do you routinely counsel these patients regarding the importance of LDL-cholesterol reduction in PAD to achieve LDL-target level?                                       Yes                                                                       No             
  Do you routinely prescribe or modify statin therapy in patients with PAD?                                                                                               a\) No                                                                                   
  b\) In few patients                                                                                                                                                                                                                                              
  c\) In majority of patients                                                                                                                                                                                                                                      
   *iv) Hypertension control*                                                                                                                                                                                                                                      
  Do you routinely measure patient's blood pressure?                                                                                                                      Yes                                                                       No             
  What is the current blood pressure target for patients with PAD?                                                                                                        a\) Unsure                                                                               
  b\) Less than 140/80 mmHg                                                                                                                                                                                                                                        
  c\) Less than 125/75 mmHg                                                                                                                                                                                                                                        
  d\) Less than 130/85 mmHg                                                                                                                                                                                                                                        
  e\) Lowest achievable                                                                                                                                                                                                                                            
  Do you routinely counsel patients regarding the importance of blood pressure control?                                                                                   Yes                                                                       No             
  Do you routinely initiate or modify antihypertensive therapy in patients with PAD?                                                                                      a\) No                                                                                   
  b\) In few patients                                                                                                                                                                                                                                              
  c\) In majority of patients                                                                                                                                                                                                                                      
   *v) Antiplatelets therapy*                                                                                                                                                                                                                                      
  Do you routinely initiate aspirin in patients with PAD?                                                                                                                 Yes                                                                       No             
  If aspirin is contraindicated or intolerable, do you prescribe other antiplatelets agents? If yes indicate the antiplatelets therapy you prescribe                      Yes                                                                       No             
  Yes                                                                                                                                                                     No                                                                                       
  (...............................)                                                                                                                                                                                                                                
   *vi) Angiotensin converting enzyme inhibitor (ACE-I) therapy*                                                                                                                                                                                                   
  Should all patients with PAD receive an ACE inhibitor irrespective of their blood pressure?                                                                             a\) If patients with PAD have normal BP, ACE-I therapy is not indicated                  
  b\) ACE-I therapy should be initiated in every patient with PAD, irrespective of their BP                                                                                                                                                                        
  c\) I am unclear what the exact recommendations regarding ACE-I in PAD are at the present time                                                                                                                                                                   
  Do you routinely initiate ACE inhibitor therapy in patients with PAD?                                                                                                   a\) No                                                                                   
  b\) In few patients                                                                                                                                                                                                                                              
  c\) In majority of patients                                                                                                                                                                                                                                      
   *vii) Management barriers in patients with PAD*                                                                                                                                                                                                                 
  What is the most important barrier to your patients with PAD not receiving risk reduction therapies, and reaching targets for vascular protection? (Chose one answer)   a\) Lack of knowledge of treating physician about PAD                                    
  b\) Lack of PAD management guidelines                                                                                                                                                                                                                            
  c\) Lack of continuing education in the importance of risk reduction approaches in global cardiovascular protection                                                                                                                                              
  d\) Absence of vascular medicine speciality in Saudi                                                                                                                                                                                                             
  e\) All of the above                                                                                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- -------------- ------------------
